1. Home
  2. Analysis
  3. Carvedilol
  4. Cotazym

Carvedilol and Cotazym drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Carvedilol (carvedilol) and Cotazym (pancrelipase (amylase;lipase;protease)). Common drug interactions include anaemia among females and cardiac failure among males.

The phase IV clinical study analyzes what interactions people have when they take Carvedilol and Cotazym. It is created by eHealthMe based on reports of 12 people who take the same drugs from the FDA, and is updated regularly.

What is Carvedilol?

Carvedilol has active ingredients of carvedilol. It is often used in high blood pressure. eHealthMe is studying from 112,651 Carvedilol users. Check the latest studies of Carvedilol.

What is Cotazym?

Cotazym has active ingredients of pancrelipase (amylase;lipase;protease). eHealthMe is studying from 377 Cotazym users. Check the latest studies of Cotazym.

eHealthMe: drug outcomes in the real world

eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.

On Sep, 02, 2026

12 people who take Carvedilol and Cotazym together, and have interactions are studied.

Carvedilol and Cotazym drug interactions.

What are the common drug interactions of Carvedilol and Cotazym, by gender? *:

female:

  1. Anaemia (lack of blood)
  2. Uterine prolapse
  3. Cataract (clouding of the lens inside the eye)
  4. Dizziness
  5. Headache (pain in head)
  6. Hypokinesia (decreased bodily movement)
  7. Injection site pain
  8. Overdose
  9. Pain in extremity
  10. Peripheral swelling

male:

  1. Cardiac failure

What are the common drug interactions of Carvedilol and Cotazym, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Anaemia (lack of blood)
  2. Body temperature decreased
  3. Cataract (clouding of the lens inside the eye)
  4. Dizziness
  5. Headache (pain in head)
  6. Hypokinesia (decreased bodily movement)
  7. Injection site pain
  8. Overdose
  9. Pain in extremity
  10. Peripheral swelling

What are the existing conditions these people have? *

  1. Pancreatic Neuroendocrine Tumor: 11 people, 91.67%
  2. Diabetes: 1 person, 8.33%

* Approximation only. Some reports may have incomplete information.

Do you take Carvedilol and Cotazym?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Carvedilol and Cotazym:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Carvedilol:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Cotazym:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Carvedilol and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Cotazym and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Related publications that referenced our studies

How the study uses the data?

The study uses data from the FDA. It is based on carvedilol and pancrelipase (amylase;lipase;protease) (the active ingredients of Carvedilol and Cotazym, respectively), and Carvedilol and Cotazym (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.